Associated Papers
Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).
Hatori M et al.
Cancer, 2024
Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.
Sito H et al.
Molecular Biology Reports, 2024
Association of the Genetic Polymorphisms RRM1 -756T>C and -269C>A With Cervical Neoplasia.
Chang CW et al.
Biological Research for Nursing, 2016
The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.
Powrózek T et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016
Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Mlak R et al.
Oncology Reports, 2013
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Cao X et al.
Pharmacogenomics, 2013
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.
Erčulj N et al.
Pharmacogenetics and Genomics, 2012
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2011
DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.
Han JY et al.
Cancer, 2011
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Metharom E et al.
Asia-pacific Journal of Clinical Oncology, 2011
Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance.
Bepler G et al.
Lung Cancer (amsterdam, Netherlands), 2005
Select a paper to view details